GlassScriptPhysician profile
Nicholas Tocci
NPI 1497441307
$2,646.59
in general payments reported to CMS, 2019-2025
22 companies · $985 in 2025
The $985 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,661 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,646.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $594.22 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $506.99 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $390.25 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $167.04 | 2024-2025 | |
| Abbvie INC. | $160.44 | 2024 | |
| Pfizer INC. | $143.12 | 2025 | |
| Abbott Laboratories | $83.14 | 2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $82.54 | 2024-2025 | Shingrix, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.07 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $67.54 | 2024-2025 | Rexulti |
| Amgen INC. | $65.60 | 2024-2025 | Repatha, Otezla, Uplizna |
| Irhythm Technologies, INC. | $59.97 | 2024 | Zio Monitor, Zio Xt Patch |
| Nevro Corp. | $58.03 | 2024 | Senza |
| Exact Sciences Corporation | $37.36 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $35.12 | 2024-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $22.75 | 2025 | Nexletol |
| Daiichi Sankyo INC. | $20.96 | 2025 | Injectafer |
| Astellas Pharma US INC | $16.99 | 2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.53 | 2024 | Caplyta |
| Xeris Pharmaceuticals, INC. | $16.27 | 2024 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $14.43 | 2025 | Inspire |
| Ossur Americas, INC. | $11.23 | 2024 | Miami J |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Tocci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.